These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 35696721)

  • 1. Multiomic Characterization of High-Grade Serous Ovarian Carcinoma Enables High-Resolution Patient Stratification.
    Hollis RL; Meynert AM; Michie CO; Rye T; Churchman M; Hallas-Potts A; Croy I; McCluggage WG; Williams ARW; Bartos C; Iida Y; Okamoto A; Dougherty B; Barrett JC; March R; Matakidou A; Roxburgh P; Semple CA; Harkin DP; Kennedy R; Herrington CS; Gourley C
    Clin Cancer Res; 2022 Aug; 28(16):3546-3556. PubMed ID: 35696721
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tumor genomic, transcriptomic, and immune profiling characterizes differential response to first-line platinum chemotherapy in high grade serous ovarian cancer.
    Weberpals JI; Pugh TJ; Marco-Casanova P; Goss GD; Andrews Wright N; Rath P; Torchia J; Fortuna A; Jones GN; Roudier MP; Bernard L; Lo B; Torti D; Leon A; Marsh K; Hodgson D; Duciaume M; Howat WJ; Lukashchuk N; Lazic SE; Whelan D; Sekhon HS
    Cancer Med; 2021 May; 10(9):3045-3058. PubMed ID: 33811746
    [TBL] [Abstract][Full Text] [Related]  

  • 3. High EMSY expression defines a BRCA-like subgroup of high-grade serous ovarian carcinoma with prolonged survival and hypersensitivity to platinum.
    Hollis RL; Churchman M; Michie CO; Rye T; Knight L; McCavigan A; Perren T; Williams ARW; McCluggage WG; Kaplan RS; Jayson GC; Oza A; Harkin DP; Herrington CS; Kennedy R; Gourley C
    Cancer; 2019 Aug; 125(16):2772-2781. PubMed ID: 31154673
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Genomic Characterization of High-Grade Serous Ovarian Cancer: Dissecting Its Molecular Heterogeneity as a Road Towards Effective Therapeutic Strategies.
    Mittempergher L
    Curr Oncol Rep; 2016 Jul; 18(7):44. PubMed ID: 27241520
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Molecular characterization of high-grade serous ovarian cancers occurring in younger and older women.
    Filippova OT; Selenica P; Pareja F; Vahdatinia M; Zhu Y; Pei X; Riaz N; Long Roche K; Chi DS; Abu-Rustum NR; Ellenson LH; Reis-Filho JS; Zamarin D; Weigelt B
    Gynecol Oncol; 2021 May; 161(2):545-552. PubMed ID: 33674143
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Classification of High-Grade Serous Ovarian Carcinoma by Epithelial-to-Mesenchymal Transition Signature and Homologous Recombination Repair Genes.
    Sohn MH; Kim SI; Shin JY; Kim HS; Chung HH; Kim JW; Lee M; Seo JS
    Genes (Basel); 2021 Jul; 12(7):. PubMed ID: 34356119
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of BRCA mutational status on survival outcome in advanced-stage high-grade serous ovarian cancer.
    Kim SI; Lee M; Kim HS; Chung HH; Kim JW; Park NH; Song YS
    J Ovarian Res; 2019 May; 12(1):40. PubMed ID: 31064392
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Low Grade Serous Ovarian Carcinoma: from the molecular characterization to the best therapeutic strategy.
    Della Pepa C; Tonini G; Santini D; Losito S; Pisano C; Di Napoli M; Cecere SC; Gargiulo P; Pignata S
    Cancer Treat Rev; 2015 Feb; 41(2):136-43. PubMed ID: 25573350
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Characterisation of homologous recombination deficiency in paired primary and recurrent high-grade serous ovarian cancer.
    Patel JN; Braicu I; Timms KM; Solimeno C; Tshiaba P; Reid J; Lanchbury JS; Darb-Esfahani S; Ganapathi MK; Sehouli J; Ganapathi RN
    Br J Cancer; 2018 Oct; 119(9):1060-1066. PubMed ID: 30318511
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Keratin 5 overexpression is associated with serous ovarian cancer recurrence and chemotherapy resistance.
    Ricciardelli C; Lokman NA; Pyragius CE; Ween MP; Macpherson AM; Ruszkiewicz A; Hoffmann P; Oehler MK
    Oncotarget; 2017 Mar; 8(11):17819-17832. PubMed ID: 28147318
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pooled Clustering of High-Grade Serous Ovarian Cancer Gene Expression Leads to Novel Consensus Subtypes Associated with Survival and Surgical Outcomes.
    Wang C; Armasu SM; Kalli KR; Maurer MJ; Heinzen EP; Keeney GL; Cliby WA; Oberg AL; Kaufmann SH; Goode EL
    Clin Cancer Res; 2017 Aug; 23(15):4077-4085. PubMed ID: 28280090
    [No Abstract]   [Full Text] [Related]  

  • 12. Prexasertib, a cell cycle checkpoint kinase 1 and 2 inhibitor, in BRCA wild-type recurrent high-grade serous ovarian cancer: a first-in-class proof-of-concept phase 2 study.
    Lee JM; Nair J; Zimmer A; Lipkowitz S; Annunziata CM; Merino MJ; Swisher EM; Harrell MI; Trepel JB; Lee MJ; Bagheri MH; Botesteanu DA; Steinberg SM; Minasian L; Ekwede I; Kohn EC
    Lancet Oncol; 2018 Feb; 19(2):207-215. PubMed ID: 29361470
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Unveiling the epigenomic mechanisms of acquired platinum-resistance in high-grade serous ovarian cancer.
    Silva R; Glennon K; Metoudi M; Moran B; Salta S; Slattery K; Treacy A; Martin T; Shaw J; Doran P; Lynch L; Jeronimo C; Perry AS; Brennan DJ
    Int J Cancer; 2023 Jul; 153(1):120-132. PubMed ID: 36883413
    [TBL] [Abstract][Full Text] [Related]  

  • 14. HOXA4/HOXB3 gene expression signature as a biomarker of recurrence in patients with high-grade serous ovarian cancer following primary cytoreductive surgery and first-line adjuvant chemotherapy.
    Miller KR; Patel JN; Zhang Q; Norris EJ; Symanowski J; Michener C; Sehouli J; Braicu I; Destephanis DD; Sutker AP; Jones W; Livasy CA; Biscotti C; Ganapathi RN; Tait DL; Ganapathi MK
    Gynecol Oncol; 2018 Apr; 149(1):155-162. PubMed ID: 29402501
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Multiomic Analysis of Subtype Evolution and Heterogeneity in High-Grade Serous Ovarian Carcinoma.
    Geistlinger L; Oh S; Ramos M; Schiffer L; LaRue RS; Henzler CM; Munro SA; Daughters C; Nelson AC; Winterhoff BJ; Chang Z; Talukdar S; Shetty M; Mullany SA; Morgan M; Parmigiani G; Birrer MJ; Qin LX; Riester M; Starr TK; Waldron L
    Cancer Res; 2020 Oct; 80(20):4335-4345. PubMed ID: 32747365
    [TBL] [Abstract][Full Text] [Related]  

  • 16. TP53 oncomorphic mutations predict resistance to platinum‑ and taxane‑based standard chemotherapy in patients diagnosed with advanced serous ovarian carcinoma.
    Brachova P; Mueting SR; Carlson MJ; Goodheart MJ; Button AM; Mott SL; Dai D; Thiel KW; Devor EJ; Leslie KK
    Int J Oncol; 2015 Feb; 46(2):607-18. PubMed ID: 25385265
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The changing view of high-grade serous ovarian cancer.
    Berns EM; Bowtell DD
    Cancer Res; 2012 Jun; 72(11):2701-4. PubMed ID: 22593197
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The copy number and mutational landscape of recurrent ovarian high-grade serous carcinoma.
    Smith P; Bradley T; Gavarró LM; Goranova T; Ennis DP; Mirza HB; De Silva D; Piskorz AM; Sauer CM; Al-Khalidi S; Funingana IG; Reinius MAV; Giannone G; Lewsley LA; Stobo J; McQueen J; Bryson G; Eldridge M; ; Macintyre G; Markowetz F; Brenton JD; McNeish IA
    Nat Commun; 2023 Jul; 14(1):4387. PubMed ID: 37474499
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparing mutation frequencies for homologous recombination genes in uterine serous and high-grade serous ovarian carcinomas: A case for homologous recombination deficiency testing in uterine serous carcinoma.
    Wallbillich JJ; Morris RT; Ali-Fehmi R
    Gynecol Oncol; 2020 Nov; 159(2):381-386. PubMed ID: 32900500
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Overexpression of ICAM-1 Predicts Poor Survival in High-Grade Serous Ovarian Carcinoma: A Study Based on TCGA and GEO Databases and Tissue Microarray.
    Wang S; Yin C; Zhang Y; Zhang L; Tao L; Liang W; Pang L; Fu R; Ding Y; Li F; Jia W
    Biomed Res Int; 2019; 2019():2867372. PubMed ID: 31312656
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.